Academic Journal

Molecular Assessment of the Potential for Renal Drug Interactions between Tenofovir and HIV Protease Inhibitors

التفاصيل البيبلوغرافية
العنوان: Molecular Assessment of the Potential for Renal Drug Interactions between Tenofovir and HIV Protease Inhibitors
المؤلفون: Cihlar, Tomas, Ray, Adrian S, Laflamme, Genevieve, Vela, Jennifer E, Tong, Leah, Fuller, Michael D, Roy, Anupma, Rhodes, Gerald R
المصدر: Antiviral Therapy ; volume 12, issue 2, page 267-272 ; ISSN 1359-6535 2040-2058
بيانات النشر: SAGE Publications
سنة النشر: 2007
الوصف: Background Active renal secretion of tenofovir (TFV) across proximal tubules occurs via uptake by human organic anion transporters 1 and 3 (hOAT1 and hOAT3) coupled with efflux by multidrug resistance protein 4 (MRP4). Co-administration of some HIV protease inhibitors (PIs) with tenofovir disoproxil fumarate (TDF), an oral prodrug of TFV, has been shown to increase systemic levels of TFV, leading to a hypothesis that PIs may affect tubular secretion of TFV and potentially alter the renal safety of TDF. Methods The effect of PIs on the transport of TFV by hOAT1, hOAT3 and MRP4 was assessed using in vitro cell-based transport models. Results At concentrations equal to their therapeutic peak plasma levels (C max ) all PIs showed <20% inhibition of TFV transport by hOAT1. hOAT3 was more sensitive to PIs with ritonavir (RTV) and lopinavir being the most potent inhibitors of TFV transport (62% and 37% inhibition, respectively, at their C max ). In the absence of human serum, RTV at concentrations exceeding its therapeutic C max also exhibited a minor effect on the cellular efflux of TFV by MRP4 (<30% inhibition at 20 μM). However, no effects of PIs on hOAT1, hOAT3 or MRP4 were detected in the presence of human serum with the exception of RTV that inhibited hOAT3 by approximately 35% at its C max . In addition, PIs did not affect the cytotoxicity of TFV or TDF in MRP4- or MRP2-overexpressing cells. Conclusion These data indicate a low potential of PIs to interfere with the active tubular secretion of TFV and to alter the clinical renal safety profile of TDF.
نوع الوثيقة: article in journal/newspaper
اللغة: English
DOI: 10.1177/135965350701200211
الاتاحة: https://doi.org/10.1177/135965350701200211
https://journals.sagepub.com/doi/pdf/10.1177/135965350701200211
Rights: https://journals.sagepub.com/page/policies/text-and-data-mining-license
رقم الانضمام: edsbas.6CF2D702
قاعدة البيانات: BASE
الوصف
DOI:10.1177/135965350701200211